The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies
![Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/researchers/kevin-harrington-appearing-on-bbc-panorama.jpg?sfvrsn=a7226f69_2)
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London
![Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY](https://embed-ssl.wistia.com/deliveries/953e1c9c808c9e24ef80c764180fa989.jpg?image_crop_resized=640x360)
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
![The ICR on Twitter: The ICR on Twitter:](https://pbs.twimg.com/media/EksuaANXIAAxAzY.jpg)
The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies
![BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment? BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?](https://ichef.bbci.co.uk/images/ic/1920x1080/p02y58py.jpg)
BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?
![Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY](https://embed-ssl.wistia.com/deliveries/29642f5bcb5b4ae4922d93c53e4f68e7.webp?image_crop_resized=1280x720)
Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
![The ICR on Twitter: The ICR on Twitter:](https://pbs.twimg.com/media/FCTe35EX0AAn_Tc.png)
The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team are using viral #Immunotherapy to harness the body's immune system to kill cancer. See their research with T-VEC, a
The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel Prize for Physiology or Medicine being awarded to
![The ICR on Twitter: The ICR on Twitter:](https://pbs.twimg.com/media/DhKm_8EVQAEXDD9.jpg)
The ICR on Twitter: "Professor Kevin Harrington introduces our world-leading work on #immunotherapy, and how we are finding new ways to tackle melanomas, head and neck, and other cancers #partneringtodefeatcancer https://t.co/Q2nRhOW9c7" /
![ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/icr-rmh-clarivate-highly-cited-researchers-2021-2-945x532.tmb-0945x532.jpg?sfvrsn=3d922b69_1)
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
![ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London](https://d1ijoxngr27nfi.cloudfront.net/images/default-source/default-album/june-dc---group.tmb-0945x532.jpg?sfvrsn=d9903069_1)
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London
The ICR on Twitter: "Professors Kevin Harrington and Alan Melcher (ICR + @royalmarsdenNHS) featured earlier in a @BBCr4today segment on #immunotherapy. In the UK you can still listen to today's live program
![The ICR on Twitter: The ICR on Twitter:](https://pbs.twimg.com/media/FUeZSb3WYAEpqX9.png)
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined
![The ICR on Twitter: The ICR on Twitter:](https://pbs.twimg.com/media/DtFiul6XgAAgVaL.jpg)